Ultralife - ULBI STOCK NEWS

Ultralife (NASDAQ: ULBI) will release its second quarter results for the period ending June 30, 2024, on July 25, 2024, before market open.

Management will host an investor conference call and webcast at 8:30 AM ET on the same day. Participants are required to pre-register for the call to ensure a smooth connection.

A live webcast will be available on the company's investor website, with a replay accessible shortly after the live broadcast.

Ultralife (NASDAQ: ULBI) has been added to the Russell 2000® Index and the broader Russell 3000® Index, effective July 1, 2024. This reconstitution of the index highlights the company's improved financial profile and earnings power. According to Mike Manna, CEO, the inclusion underscores Ultralife's success in new product investments and margin recapture. The addition to these indexes is expected to increase visibility among institutional investors, aiding in the company’s goal for sustainable, profitable growth. The annual reconstitution identifies the 4,000 largest U.S. stocks by market capitalization as of April 30, 2024, and this inclusion will hold for one year.

Ultralife (NASDAQ: ULBI) reported strong first-quarter results with sales of $41.9 million, a 31.4% increase year-over-year. Gross profit was $11.5 million, operating income reached $4.1 million, and GAAP EPS stood at $0.18. Adjusted EBITDA saw a significant gain to $5.2 million. The company emphasized gross margin improvement and growth in government/defense and medical markets. Revenue increase was driven by battery & Energy Products and Communications Systems sales growth. Ultralife remains optimistic about sustaining profitable growth, generating cash flow, and investing in new products and acquisitions.

Ultralife (NASDAQ: ULBI) will announce its first quarter results for the period ending March 31, 2024, on April 25, 2024. The company's Management will conduct an investor conference call and webcast at 8:30 AM ET on the same day. Participants are required to pre-register for the call to ensure a smooth connection.

Ultralife Corporation (ULBI) reported strong operating results for Q4 and FY 2023, with sales reaching $44.5 million in Q4, a 23.4% YoY increase, and $158.6 million for the fiscal year, a 20.3% YoY increase. Adjusted EBITDA doubled in Q4, reaching $4.8 million, and increased to $15.7 million for the year. The company saw a significant expansion in gross margin to 24.7% for the year, resulting in adjusted EPS of $0.52. Ultralife aims to reduce debt, invest in new products, and sustain profitable growth in 2024.

Ultralife Corporation (NASDAQ: ULBI) will report its fourth quarter results for the period ended December 31, 2023 before the market opens on Thursday, February 15, 2024. Ultralife’s Management will also host an investor conference call and simultaneous webcast at 8:30 AM ET on February 15, 2024. Participants dialing in by phone are required to pre-register using the provided link to ensure a fast and reliable connection to the investor conference call. A live webcast of the conference call will be available to investors on the Company’s website, with a replay available shortly after the call at the same location.

Ultralife Corporation reports Q3 2023 results with sales of $39.5 million, a 18.8% YoY increase. Operating income of $2.1 million, compared to a loss of $0.6 million in Q3 2022. Adjusted EPS of $0.10, compared to a loss of $0.03 in Q3 2022. Adjusted EBITDA of $3.5 million, a 177.3% YoY increase. Backlog of $101.1 million.

Ultralife Corporation to report Q3 results on October 26, 2023

Ultralife Corporation (NASDAQ: ULBI) reported operating results for Q2 2023. Sales increased by 32.9% YoY to $42.7 million. Operating income was $3.7 million compared to $0.8 million in Q2 2022. Adjusted EPS was $0.29 compared to $0.03 in the previous year. Backlog increased to $110.9 million, the highest level in the company's history.